Athenex, Inc.
ATNXDrugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Oraxol
Metastatic Breast Cancer
KX2-391 Ointment 1%
Actinic Keratoses
KX2-391
Bone-Metastatic, Castration-Resistant Prostate Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Oraxol | Phase 3 | Metastatic Breast Cancer | - | - |
KX2-391 Ointment 1% | Phase 3 | Actinic Keratoses | - | - |
KX2-391 | Phase 2 | Bone-Metastatic, Castration-Resistant Prostate Cancer | - | - |
Metastatic Breast Cancer
1 drug in this indication
Bone-Metastatic, Castration-Resistant Prostate Cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Athenex, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Athenex, Inc.'s (ATNX) pipeline across Phase 3, Phase 2. Its lead program is Oraxol (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Athenex, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Athenex, Inc. (ATNX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ATNX biotech catalysts?→
Add ATNX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Athenex, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.